Genomics

Pluristyx and Solesis launch a 'three-in-one' kit with nearly 100% efficiency in iPSC transfection, tackling a major bottleneck in organoid research.

A new study reveals Exicure's burixafor mobilizes stem cells in one hour, promising to streamline cancer treatment and unlock future gene therapies.

VectorY Therapeutics adds seasoned biotech architect Kevin Pojasek to its board, signaling a strategic push to accelerate its novel therapies for ALS and Alzheimer's.

Life sciences giant QIAGEN defies economic headwinds with strong 2025 results, signaling aggressive growth in single-cell analysis and bioinformatics.

A nationwide study, with NFL legend Steve Gleason as Participant #1, seeks to uncover why high-performance groups face a disproportionate risk of ALS.

Caribou Biosciences unveils new data showing its 'off-the-shelf' CAR-T cells achieve deep, lasting responses in lymphoma and myeloma clinical trials.

An expanded partnership aims to deliver a once-daily oral tablet for hypoparathyroidism, potentially revolutionizing treatment for thousands of patients.

Affinia Therapeutics gets the green light for a human trial of AFTX-201, a one-time therapy for a devastating genetic heart disease, BAG3 DCM.

With crucial data on its novel oral inflammation inhibitor looming, NodThera brings in seasoned leader Geoff McDonough to navigate the path to Phase 3.

A powerful new genomic tool is turning genetic doubt into diagnostic certainty, helping thousands of patients understand their true hereditary cancer risk.

New 4-year real-world data shows Zevra's drug stabilizes the rare, fatal 'Childhood Alzheimer's' disease, marking a milestone for patients and families.

Organon expands its Women's Health Accelerator to META, aiming to close health gaps and unlock a potential £1 trillion economic boost through digital innovation.

A new bipartisan law injects vital funds into neuromuscular disease research, a victory driven by years of relentless patient advocacy. Here's what it means.

After a four-year campaign, the World Health Organization is poised to recognize a silent liver epidemic, setting the stage for a new global NCD strategy.

Regulators deem PRRS-resistant pigs safe, promising a future with less animal disease and antibiotic use, but sparking debate on consumer transparency.

A new AI-powered blood test from CareDx shows promise in detecting cancer relapse weeks earlier, offering new hope for transplant patients.

Pharming Group projects strong 2026 growth, fueling ambitious clinical programs for rare immunodeficiencies and mitochondrial diseases.

JScreen, Manischewitz, and advocate Gila Pfeffer offer low-cost cancer and carrier genetic tests in NYC, transforming community health access.

A new liquid biopsy more accurately predicts cancer recurrence than standard methods, offering new hope and clarity for patients after surgery.

Promising Phase 2 data for a potential first-in-class neuropathic corneal pain therapy to be showcased, offering new hope for a debilitating condition.